Abstract
Doxorubicin is one of the most commonly used chemotherapeutic drugs for breast cancer; however, its use is limited by drug resistance and side effects. We hypothesized that adding FTY720, a sphingosine-1-phosphate (S1P) receptor functional antagonist, to doxorubicin would potentiate its effects by suppression of drug-induced inflammation. The Cancer Genome Atlas, Gene Expression Omnibus data sets, and National Cancer Institute-60 panel were used for gene expressions and gene set enrichment analysis. E0771 syngeneic mammary tumor cells were used. OB/OB mice fed with western high-fat diet were used as an obesity model. STAT3 expression was significantly increased after doxorubicin treatment in human breast cancer that implicates that doxorubicin evokes inflammation. Expression of sphingosine kinase 1, the enzyme that produces S1P and links inflammation and cancer, tended to be higher in doxorubicin-resistant human cancer and cell lines. In a murine breast cancer model, sphingosine kinase 1, S1P receptor 1, interleukin 6, and STAT3 were overexpressed in the doxorubicin-treated group, whereas all of them were significantly suppressed with addition of FTY720. Combination therapy synergistically suppressed cancer growth both in vitro...Continue Reading
Citations
Sep 5, 2017·International Journal of Molecular Sciences·Nahal HaddadiEileen M McGowan
Jun 21, 2018·Cancer Medicine·Fu-Ju LeiWen-Lung Ma
Aug 6, 2019·Advanced Healthcare Materials·Mohammad TalebGuangjun Nie
Feb 29, 2020·Journal of Mammary Gland Biology and Neoplasia·Maiko OkanoKazuaki Takabe
Mar 28, 2018·Oncotarget·Tomoaki TerakawaKazuaki Takabe
Jun 4, 2020·International Journal of Molecular Sciences·Eriko KatsutaKazuaki Takabe
Jul 12, 2020·Cells·Masanori OshiKazuaki Takabe
Jun 9, 2020·Human Cell·Eriko KatsutaKazuaki Takabe
Jul 30, 2020·Cancers·Hideo TakahashiKazuaki Takabe
Sep 17, 2020·International Journal of Molecular Sciences·Masanori OshiKazuaki Takabe
Jun 4, 2018·Investigational New Drugs·Shujun Xiao, Jian Yang
Jul 19, 2018·Scientific Reports·Yuki HiroseToshifumi Wakai
Apr 9, 2020·Frontiers in Oncology·Heba AlshakerDmitri Pchejetski
May 7, 2020·International Journal of Molecular Sciences·Yoshihisa TokumaruKazuaki Takabe
Aug 17, 2020·International Journal of Molecular Sciences·Yoshihisa TokumaruKazuaki Takabe
Jul 18, 2018·Oxidative Medicine and Cellular Longevity·Márcia Fernanda Correia Jardim PazJuliana da Silva
Jan 8, 2020·International Journal of Molecular Sciences·Eriko KatsutaKazuaki Takabe
Oct 8, 2020·Cancer Medicine·Augustin Le NaourMarie-Paule Vasson
Jan 21, 2018·Cancer Research·Masayuki NagahashiKazuaki Takabe
Dec 3, 2020·Cancers·Masanori OshiKazuaki Takabe
Jan 19, 2021·Journal of Immunology Research·Masanori OshiKazuaki Takabe
Jun 7, 2019·Surgery·Hideo TakahashiKazuaki Takabe
Nov 12, 2019·Advances in Biological Regulation·Sandeep K Singh, Sarah Spiegel
Mar 25, 2021·Curēus·Dutt S PatelDomonick K Gordon
Apr 20, 2021·Therapeutic Advances in Medical Oncology·Eriko KatsutaKazuaki Takabe
Jun 2, 2021·Journal of Nanobiotechnology·Ke GongYourong Duan
Jun 17, 2021·Scientific Reports·Masanori OshiKazuaki Takabe